References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer [internet publication].Full text
National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. March 2024 [internet publication].Full text
European Society for Medical Oncology. Oncogene-mediated metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Jan 2023 [internet publication].Full text
Hendriks L E, Kerr K, Menis J, et al. on behalf of the ESMO Guidelines Committee. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Jan 2023;34(4):358-76.Full text
Reuss JE, Kuruvilla S, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2025.1. J Clin Oncol. 2025 Aug 20;43(24):e31-44.Full text Abstract
Owen DH, Halmos B, Puri S, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1. J Clin Oncol. 2025 Aug 20;43(24):e45-58.Full text Abstract
Reference articles
1. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94. Abstract
2. WHO Classification of Tumours Editorial Board. Thoracic tumours: World Health Organization classification of tumours. 5th ed, vol 3. Lyon, France: International Agency for Research on Cancer; 2021.Full text
3. Ost DE, Yeung SC, Tanoue LT, et al. Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e121S-e141S.Full text Abstract
4. Wudel LJ, Nesbitt JC. Superior vena cava syndrome. Curr Treat Options Oncol. 2001 Feb;2(1):77-91. Abstract
5. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). 2002 Oct;14(5):338-51.Full text Abstract
6. Beckles MA, Spiro SG, Colice GL, et al. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003 Jan;123(1 Suppl):97S-104S. Abstract
7. Archie VC, Thomas CR Jr. Superior sulcus tumors: a mini-review. Oncologist. 2004 Sep 1;9(5):550-5.Full text Abstract
8. Foroulis CN, Zarogoulidis P, Darwiche K, et al. Superior sulcus (Pancoast) tumors: current evidence on diagnosis and radical treatment. J Thorac Dis. 2013 Sep;5 Suppl 4(suppl 4):S342-58.Full text Abstract
9. Attar S, Krasna MJ, Sonett JR, et al. Superior sulcus (Pancoast) tumor: experience with 105 patients. Ann Thorac Surg. 1998 Jul;66(1):193-8.Full text Abstract
10. Bradley SH, Kennedy MPT, Neal RD. Recognising lung cancer in primary care. Adv Ther. 2019 Jan;36(1):19-30.Full text Abstract
11. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011 Nov 12;378(9804):1741-55. Abstract
12. American Cancer Society. Key statistics for lung cancer. Jan 2025 [internet publication].Full text
13. World Health Organization. Lung cancer: fact sheet. Jun 2023 [internet publication].Full text
14. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.Full text Abstract
15. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: lung and bronchus cancer [internet publication].Full text
16. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.Full text Abstract
17. GBD 2019 Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respir Med. 2021 Sep;9(9):1030-49.Full text Abstract
18. Centers for Disease Control and Prevention. Burden of cigarette use in the US. Oct 2024 [internet publication].Full text
19. Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene. 2002 Oct 7;21(45):6870-6. Abstract
20. Centers for Disease Control and Prevention. Lung cancer: lung cancer among people who never smoked. Oct 24 [internet publication].Full text
21. Ngoc LTN, Park D, Lee YC. Human health impacts of residential radon exposure: updated systematic review and meta-analysis of case-control studies. Int J Environ Res Public Health. 2022 Dec 21;20(1):97.Full text Abstract
22. Darby S, Hill D, Deo H, et al. Residential radon and lung cancer--detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. Scand J Work Environ Health. 2006;32 (suppl 1):1-83.Full text Abstract
23. Curiel-García T, Rey-Brandariz J, Varela-Lema L, et al. Asbestos exposure and small cell lung cancer: systematic review and meta-analysis. J Occup Environ Hyg. 2023 Oct;20(10):427-38. Abstract
24. Nielsen LS, Bælum J, Rasmussen J, et al. Occupational asbestos exposure and lung cancer--a systematic review of the literature. Arch Environ Occup Health. 2014;69(4):191-206. Abstract
25. Raaschou-Neilsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol. 2013 Aug;14(9):813-22. Abstract
26. Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023 Nov;24(11):1206-18. Abstract
27. Subramanian J, Morgensztern D, Goodgame B, et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol. 2010 Jan;5(1):23-8. Abstract
28. Franks TJ, Galvin JR. Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis. Arch Pathol Lab Med. 2010 Jan;134(1):49-54.Full text Abstract
29. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85. Abstract
30. Takahashi S, Tanaka N, Okimoto T, et al. Long term follow-up for small pure ground-glass nodules: implications of determining an optimum follow-up period and high-resolution CT findings to predict the growth of nodules. Jpn J Radiol. 2012 Apr;30(3):206-17. Abstract
31. Kim TJ, Park CM, Goo JM, et al. Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity? AJR Am J Roentgenol. 2012 Jan;198(1):83-8.Full text Abstract
32. Kim TJ, Goo JM, Lee KW, et al. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer. 2009 May;64(2):171-8. Abstract
33. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology. 2009 Jan;54(1):12-27. Abstract
34. Doll R, Hill D. Smoking and carcinoma of the lung; a preliminary report. BMJ. 1950 Sep 30;2(4682):739-48. Abstract
35. Levin ML, Goldstein H, Gerhardt PR. Cancer and tobacco smoking; a preliminary report. JAMA. 1950 May 27;143(4):336-8. Abstract
36. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of six hundred and eighty-four proved cases. JAMA. 1950 May 27;143(4):329-36. Abstract
37. Pérez-Ríos M, López-Medina DC, Guerra-Tort C, et al. Mortality attributable to environmental tobacco smoke exposure in Spain in 2020. [in spa]. Arch Bronconeumol. 2023 May;59(5):305-10.Full text Abstract
38. Hori M, Tanaka H, Wakai K, et al. Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies. Jpn J Clin Oncol. 2016 Oct;46(10):942-51.Full text Abstract
39. Copas JB, Shi JQ. Reanalysis of epidemiological evidence on lung cancer and passive smoking. BMJ. 2000 Feb 12;320(7232):417-8.Full text Abstract
40. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009 Aug;34(2):380-6.Full text Abstract
41. Gonzalez J, Marín M, Sánchez-Salcedo P, et al. Lung cancer screening in patients with chronic obstructive pulmonary disease. Ann Transl Med. 2016 Apr;4(8):160.Full text Abstract
42. Zhang Z, Zhang X, Gao Y, et al. Risk factors for the development of lung cancer among never smokers: a systematic review. Cancer Epidemiol. 2022 Dec;81:102274.Full text Abstract
43. Park HY, Kang D, Shin SH, et al. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study. Thorax. 2020 Jun;75(6):506-9.Full text Abstract
44. Powell HA, Iyen-Omofoman B, Baldwin DR, et al. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol. 2013 Apr;8(4):e34-5. Abstract
45. Nitadori J, Inoue M, Iwasaki M, et al. Association between lung cancer incidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC study. Chest. 2006 Oct;130(4):968-75. Abstract
46. Cassidy A, Myles JP, Duffy SW, et al. Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives. Br J Cancer. 2006 Nov 6;95(9):1288-90.Full text Abstract
47. Kelly-Reif K, Bertke SJ, Rage E, et al. Radon and lung cancer in the pooled uranium miners analysis (PUMA): highly exposed early miners and all miners. Occup Environ Med. 2023 Jul;80(7):385-91. Abstract
48. Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ. 2005 Jan 29;330(7485):223.Full text Abstract
49. World Health Organization. Radon and health. Jan 2023 [internet publication].Full text
50. Milner J, Shrubsole C, Das P, et al. Home energy efficiency and radon related risk of lung cancer: modelling study. BMJ. 2014 Jan 10;348:f7493.Full text Abstract
51. Leone FT, Evers-Casey S, Toll BA, et al. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e61S-e77S.Full text Abstract
52. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Full text Abstract
53. Cortés-Jofré M, Rueda JR, Asenjo-Lobos C, et al. Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD002141.Full text Abstract
54. US Preventive Services Task Force; Mangione CM, Barry MJ, et al. Vitamin, mineral, and multivitamin supplementation to prevent cardiovascular disease and cancer: US Preventive Services Task Force recommendation statement. JAMA. 2022 Jun 21;327(23):2326-33.Full text Abstract
55. Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: diagnosis and management of lung cancer. 3rd ed. American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e455S-e497S.Full text Abstract
56. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med. 1989 May;149(5):1076-80. Abstract
57. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022 Feb 10;40(5):492-516.Full text Abstract
58. Marulli G, Battistella L, Mammana M, et al. Superior sulcus tumors (Pancoast tumors). Ann Transl Med. 2016 Jun;4(12):239.Full text Abstract
59. American College of Radiology. ACR appropriateness criteria: noninvasive clinical staging of primary lung cancer. 2018 [internet publication].Full text
60. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer [internet publication].Full text
61. National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. March 2024 [internet publication].Full text
62. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e142S-e165S.Full text Abstract
63. Schwartz AM, Rezaei MK. Diagnostic surgical pathology in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e251S-e262S.Full text Abstract
64. Blum TG, Morgan RL, Durieux V, et al. European Respiratory Society guideline on various aspects of quality in lung cancer care. Eur Respir J. 2023 Feb;61(2):2103201.Full text Abstract
65. Thunnissen FB. Sputum examination for early detection of lung cancer. J Clin Pathol. 2003 Nov;56(11):805-10. Abstract
66. National Institute for Health and Care Excellence. Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. February 2008 [internet publication].Full text
67. Adams K, Shah PL, Edmonds L, et al. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax. 2009 Sep;64(9):757-62. Abstract
68. Gu P, Zhao YZ, Jiang LY, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer. 2009 May;45(8):1389-96. Abstract
69. Varela-Lema L, Fernandez-Villar A, Ruano-Ravina A, et al. Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review. Eur Respir J. 2009 May;33(5):1156-64. Abstract
70. Chen W, Gao X, Tian Q, et al. A comparison of autofluorescence bronchoscopy and white light bronchoscopy in detection of lung cancer and preneoplastic lesions: a meta-analysis. Lung Cancer. 2011 Aug;73(2):183-8. Abstract
71. Sun J, Garfield DH, Lam B, et al. The value of autofluorescence bronchoscopy combined with white light bronchoscopy compared with white light alone in the diagnosis of intraepithelial neoplasia and invasive lung cancer: a meta-analysis. J Thorac Oncol. 2011 Aug;6(8):1336-44. Abstract
72. Zhang J, Wu J, Yang Y, et al. White light, autofluorescence and narrow-band imaging bronchoscopy for diagnosing airway pre-cancerous and early cancer lesions: a systematic review and meta-analysis. J Thorac Dis. 2016 Nov;8(11):3205-16.Full text Abstract
73. Port J, Harrison S. Electromagnetic navigational bronchoscopy. Semin Intervent Radiol. 2013 Jun;30(2):128-32.Full text Abstract
74. Kang HJ, Hwangbo B, Lee GK, et al. EBUS-centred versus EUS-centred mediastinal staging in lung cancer: a randomised controlled trial. Thorax. 2014 Mar;69(3):261-8. Abstract
75. Dubé JP, Azzi Z, Semionov A, et al. Imaging of post transthoracic needle biopsy complications. Can Assoc Radiol J. 2019 May;70(2):156-163.Full text Abstract
76. Asciak R, Bedawi EO, Bhatnagar R, et al. British Thoracic Society Clinical Statement on pleural procedures. Thorax. 2023 Jul;78(suppl 3):s43-s68.Full text Abstract
77. Akram AR, Hartung TK. Intercostal chest drains: a wake-up call from the National Patient Safety Agency rapid response report. J R Coll Physicians Edinb. 2009;39:117-120.Full text
78. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e211S-e250S.Full text Abstract
79. Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010 Nov 24;304(20):2245-52.Full text Abstract
80. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015 Jun;47(6):545-59.Full text Abstract
81. Kumaran M, Benamore RE, Vaidhyanath R, et al. Ultrasound guided cytological aspiration of supraclavicular lymph nodes in patients with suspected lung cancer. Thorax. 2005 Mar;60(3):229-33. Abstract
82. Rodrigues M, Stark H, Rendl G, et al. Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients. Q J Nucl Med Mol Imaging. 2016 Mar;60(1):62-8.Full text Abstract
83. European Society for Medical Oncology. Oncogene-mediated metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Jan 2023 [internet publication].Full text
84. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012 Mar 10;30(8):863-70.Full text Abstract
85. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011 Sep 10;29(26):3574-9.Full text Abstract
86. Cui G, Liu D, Li W, et al. A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer. Medicine (Baltimore). 2017 Apr;96(14):e6552. Abstract
87. Gautschi O, Milia J, Filleron T, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol. 2017 May 1;35(13):1403-10.Full text Abstract
88. Michels S, Scheel AH, Scheffler M, et al. Clinicopathological characteristics of RET rearranged lung cancer in European patients. J Thorac Oncol. 2016 Jan;11(1):122-7.Full text Abstract
89. Schram AM, Goto K, Kim DW, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. 2025 Feb 6;392(6):566-76.Full text Abstract
90. Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol. 2024 Sep 1;42(25):3000-11.Full text Abstract
91. Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018 Sept;13(9):1302-11.Full text Abstract
92. Hendriks L E, Kerr K, Menis J, et al. on behalf of the ESMO Guidelines Committee. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Jan 2023;34(4):358-76.Full text
93. Miller KL, Shafman TD, Marks LB. A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer. Semin Radiat Oncol. 2004 Oct;14(4):298-307. Abstract
94. Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e166S-e190S.Full text Abstract
95. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. Abstract
96. Kvale PA. Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1 suppl):147S-53S.Full text Abstract
97. Razazi K, Parrot A, Khalil A, et al. Severe haemoptysis in patients with nonsmall cell lung carcinoma. Eur Respir J. 2015 Mar;45(3):756-64.Full text Abstract
98. Chamberlain MC, Baik CS, Gadi VK, et al. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol. 2017 Jan;19(1):i1-24.Full text Abstract
99. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012 Feb;14(1):48-54. Abstract
100. Dawe DE, Greenspoon JN, Ellis PM. Brain metastases in non-small-cell lung cancer. Clin Lung Cancer. 2014 Jul;15(4):249-57. Abstract
101. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5.Full text Abstract
102. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000 Feb;117(2):358-64. Abstract
103. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest. 1998 Dec;114(6):1535-7. Abstract
104. Magnusson A, Andersson T, Larsson B, et al. Contrast enhancement of pathologic lymph nodes demonstrated by computed tomography. Acta Radiol. 1989 May-Jun;30(3):307-10. Abstract
105. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 1999 Nov;213(2):530-6. Abstract
106. Toloza EM, Harpole L, Detterbeck F, et al. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 suppl):157S-166S. Abstract
107. Porcel JM, Pardina M, Bielsa S, et al. Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions. Chest. 2015 Feb;147(2):513-9. Abstract
108. Herth FJF. Bronchoscopy and bleeding risk. Eur Respir Rev. 2017 Sep 30;26(145):170052.Full text Abstract
109. Kuijvenhoven JC, Leoncini F, Crombag LC, et al. Endobronchial ultrasound for the diagnosis of centrally located lung tumors: a systematic review and meta-analysis. Respiration. 2020;99(5):441-50.Full text Abstract
110. Steinfort DP, Khor YH, Manser RL, et al. Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis. Eur Respir J. 2011 Apr;37(4):902-10.Full text Abstract
111. Micames CG, McCrory DC, Pavey DA, et al. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: a systematic review and metaanalysis. Chest. 2007 Feb;131(2):539-48. Abstract
112. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 suppl):137S-146S. Abstract
113. Schmidt-Hansen M, Baldwin DR, Hasler E, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014 Nov 13;(11):CD009519.Full text Abstract
114. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA. 2014 Sep 24;312(12):1227-36.Full text Abstract
115. Shreenivas A, Janku F, Gouda MA, et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023 Sep 29;7(1):101.Full text Abstract
116. Ozkaya S, Bilgin S, Hamsici S, et al. The pulmonary radiologic findings of rheumatoid arthritis. Respir Med CME. 2011;4(4):187-92.Full text
117. American College of Surgeons. AJCC version 9 cancer staging system: lung. 2025 [internet publication]Full text
118. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. Abstract
119. Bonney A, Malouf R, Marchal C, et al. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. Cochrane Database Syst Rev. 2022 Aug 3;8(8):CD013829.Full text Abstract
120. Aberle DR, Adams AM, Berg CD, et al; The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409.Full text Abstract
121. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020 Feb 6;382(6):503-13.Full text Abstract
122. US Preventive Services Task Force. Lung cancer: screening. March 2021 [internet publication].Full text
123. American College of Radiology. ACR appropriateness criteria®: lung cancer screening. 2022 [internet publication].Full text
124. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: lung cancer screening [internet publication].Full text
125. American Cancer Society. Lung cancer screening guidelines. Jan 2024 [internet publication].Full text
126. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42.Full text Abstract
127. Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018 Jul-Aug;8(4):245-50.Full text Abstract
128. Brunelli A, Charloux A, Bolliger CT, et al.; European Respiratory Society; European Society of Thoracic Surgeons Joint Task Force on Fitness For Radical Therapy. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009 Jul;36(1):181-4.Full text Abstract
129. Postmus PE, Kerr KM, Oudkerk M, et al.; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–21.Full text
130. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22. Abstract
131. Pezzi CM, Mallin K, Mendez AS, et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg. 2014 Nov;148(5):2269-77.Full text Abstract
132. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e278S-e313S.Full text Abstract
133. Myrdal G, Gustafsson G, Lambe M, et al. Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity. Eur J Cardiothorac Surg. 2001 Oct;20(4):694-9.Full text Abstract
134. Powell HA, Tata LJ, Baldwin DR, et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax. 2013 Sep;68(9):826-34.Full text Abstract
135. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 May 26;386(21):1973-85. Abstract
136. Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024 May 16;390(19):1756-69.Full text Abstract
137. Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023 Aug 10;389(6):491-503.Full text Abstract
138. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023 Nov 2;389(18):1672-84.Full text Abstract
139. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014 May 3;383(9928):1561-71.Full text Abstract
140. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol. 2005 Jun 1;23(suppl 1):624.
141. Ligibel JA, Bohlke K, Alfano CM. Exercise, diet, and weight management during cancer treatment: ASCO guideline summary and Q&A. JCO Oncol Pract. 2022 Jul 5;OP2200277.Full text Abstract
142. Granger C, Cavalheri V. Preoperative exercise training for people with non-small cell lung cancer. Cochrane Database Syst Rev. 2022 Sep 28;9(9):CD012020.Full text Abstract
143. Cavalheri V, Burtin C, Formico VR, et al. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database Syst Rev. 2019 Jun 17;6:CD009955.Full text Abstract
144. Gravier FE, Smondack P, Prieur G, et al. Effects of exercise training in people with non-small cell lung cancer before lung resection: a systematic review and meta-analysis. Thorax. 2022 May;77(5):486-496.Full text Abstract
145. Arriagada R, Bergman B, Dunant A, et al; The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004 Jan 22;350(4):351-60.Full text Abstract
146. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. Abstract
147. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97.Full text Abstract
148. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42. Abstract
149. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 1;28(1):29-34.Full text Abstract
150. Burdett S, Pignon JP, Tierney J, et al; Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015 Mar 2;(3):CD011430.Full text Abstract
151. Pisters K, Kris MG, Gaspar LE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Apr 1;40(10):1127-29.Full text Abstract
152. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010 Apr 10;375(9722):1267-77.Full text Abstract
153. Bradbury P, Sivajohanathan D, Chan A, et al. Postoperative adjuvant systemic therapy in completely resected non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017 May;18(3):259-73.e8. Abstract
155. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-57. Abstract
156. O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-86. Abstract
157. Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024 Apr 11;390(14):1265-76.Full text Abstract
158. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020 Oct 29;383(18):1711-23.Full text Abstract
159. Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023 Apr 1;41(10):1830-40.Full text Abstract
160. Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-47.Full text Abstract
161. Singh N, Daly ME, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Sep 20;41(27):4430-2.Full text Abstract
162. O'Reilly D, Botticella A, Barry S, et al. Treatment decisions for resectable non-small-cell lung cancer: balancing less with more? Am Soc Clin Oncol Educ Book. 2023 May;43:e389950.Full text Abstract
163. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998 Jul 25;352(9124):257-63. Abstract
164. Ruysscher D, Wauters E, Jendrossek V, et al. Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: an ESTRO clinical practice guideline. Radiother Oncol. 2025 Jun;207:110837.Full text Abstract
165. Bledsoe TJ, Nath SK, Decker RH. Radiation pneumonitis. Clin Chest Med. 2017 Jun;38(2):201-8. Abstract
166. Luchini C, Veronese N, Nottegar A, et al. Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. Virchows Arch. 2018 Jun;472(6):939-47. Abstract
167. Lester JF, Coles B, Macbeth FR. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005221.Full text Abstract
168. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31. Abstract
169. Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019 Apr;20(4):494-503. Abstract
170. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006 Oct 20;24(30):4833-9. Abstract
171. Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1149-56. Abstract
172. Wang J, Li B, Zhang L, et al. Safety and local efficacy of computed tomography-guided microwave ablation for treating early-stage non-small cell lung cancer adjacent to bronchovascular bundles. Eur Radiol. 2024 Jan;34(1):236-46.Full text Abstract
173. Fintelmann FJ, Graur A, Oueidat K, et al. Ablation of stage I-II non-small cell lung cancer in patients with interstitial lung disease: a multicenter retrospective study. AJR Am J Roentgenol. 2024 Feb;222(2):e2330300.Full text Abstract
174. National Institute for Health and Care Excellence. Percutaneous radiofrequency ablation for primary or secondary lung cancers. December 2010 [internet publication].Full text
175. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e314S-e340S.Full text Abstract
176. Daly ME, Singh N, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022 Apr 20;40(12):1356-84.Full text Abstract
177. Putora PM, Leskow P, McDonald F, et al. International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Res. 2020 Jan;6(1):00159-2019.Full text Abstract
178. Simone CB 2nd, Bradley J, Chen AB, et al. ASTRO radiation therapy summary of the ASCO guideline on management of stage III non-small cell lung cancer. Pract Radiat Oncol. 2023 May-Jun;13(3):195-202.Full text Abstract
179. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9. Abstract
180. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC. Proc Am Soc Clin Oncol. 2003 Jan 1;22:621.
181. van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007 Mar 21;99(6):442-50.Full text Abstract
182. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342-50.Full text Abstract
183. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919-29.Full text Abstract
184. National Institute for Health and Care Excellence. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. Jun 2022 [internet publication].Full text
185. Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024 Aug 15;391(7):585-97. Abstract
186. Daly ME, Singh N, Ismaila N, et al. Management of stage III non-small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2024 Sep 1;42(25):3058-60.Full text Abstract
187. Iyengar P, All S, Berry MF, et al. Treatment of oligometastatic non-small cell lung cancer: an ASTRO/ESTRO clinical practice guideline. Pract Radiat Oncol. 2023 Sep-Oct;13(5):393-412.Full text Abstract
188. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].Full text
189. Inoue A, Kobayashi K, Usui K,et al; North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009 Mar 20;27(9):1394-400.Full text Abstract
190. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(suppl 4):iv192-iv237.Full text Abstract
191. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. Abstract
192. Greenhalgh J, Boland A, Bates V, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD010383.Full text Abstract
193. Reuss JE, Kuruvilla S, Ismaila N, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2025.1. J Clin Oncol. 2025 Aug 20;43(24):e31-44.Full text Abstract
194. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-48.Full text Abstract
195. Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024 Oct 24;391(16):1486-98. Abstract
196. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113-25. Abstract
197. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50.Full text Abstract
198. Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018 Aug 28:JCO2018783118.Full text Abstract
199. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-69. Abstract
200. Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. Abstract
201. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-66. Abstract
202. Deng W, Wang K, Jiang Y, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2022 Aug 19;12(8):e062036.Full text Abstract
203. Cappuzzo F, Ciuleanu T, Stelmakh L, et al; SATURN Investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. Abstract
204. Rosell R, Moran T, Queralt C, et al; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958-67.Full text Abstract
205. Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020 Feb 10;38(5):488-95.Full text Abstract
206. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8. Abstract
207. Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453.Full text Abstract
208. Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023 Apr;11(4):354-66. Abstract
209. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021 Dec;16(12):2091-08.Full text Abstract
210. Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021 Nov 1;7(11):1617-25.Full text Abstract
211. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963-71.Full text Abstract
212. Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-70.Full text Abstract
213. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-82.Full text Abstract
214. Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024 Jan 11;390(2):118-31.Full text Abstract
215. Pérol M, Li W, Pennell NA, et al. Taletrectinib in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol. 2025 Jun;43(16):1920-9.Full text Abstract
216. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93.Full text Abstract
217. Riely GJ, Smit EF, Ahn MJ, et al. Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer. J Clin Oncol. 2023 Jul 20;41(21):3700-11.Full text Abstract
218. Subbiah V, Gervais R, Riely G, et al. Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol. 2019 Jun 27;3:PO.18.00266.Full text Abstract
219. Wu YL, Zhang L, Kim DW, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018 Nov 1;36(31):3101-09.Full text Abstract
220. Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020 Sep 3;383(10):944-57.Full text Abstract
221. Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020 Jan;26(1):47-51. Abstract
222. Le X, Paz-Ares LG, Van Meerbeeck J, et al. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Rep Med. 2023 Nov 21;4(11):101280.Full text Abstract
223. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020 Aug 27;383(9):813-24.Full text Abstract
224. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 Jul;22(7):959-69. Abstract
225. Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023 Jan 10;41(2):385-94.Full text Abstract
226. Zhou C, Solomon B, Loong HH, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023 Nov 16;389(20):1839-50.Full text Abstract
227. Poumeaud F, Jaffrelot M, Gomez-Roca C, et al. A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review. Front Med (Lausanne). 2024;11:1402902.Full text Abstract
228. European Society for Medical Oncology. Pralsetinib: measures to minimise increased risk for tuberculosis. May 2023 [internet publication].Full text
229. Yin Y, Sun F, Jin Y. A real-world pharmacovigilance study of FDA adverse event reporting system events for pralsetinib. Front Oncol. 2024;14:1491167.Full text Abstract
230. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021 Jun 24;384(25):2371-81.Full text Abstract
231. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N Engl J Med. 2022 Jul 14;387(2):120-31.Full text Abstract
232. de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 Mar 4;401(10378):733-46. Abstract
233. Dy GK, Govindan R, Velcheti V, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol. 2023 Jun 20;41(18):3311-7.Full text Abstract
234. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-9.Full text Abstract
235. Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Ann Oncol. 2023;34:S787-8.Full text
236. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022 Jan 20;386(3):241-51.Full text Abstract
237. Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025 Jun 19;392(23):2321-33. Abstract
238. Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018 Aug 20;36(24):2532-7.Full text Abstract
239. Brazel D, Kroening G, Nagasaka M. Non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: diagnosis and treatment options. BioDrugs. 2022 Nov;36(6):717-29.Full text Abstract
240. Owen DH, Halmos B, Puri S, et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, version 2025.1. J Clin Oncol. 2025 Aug 20;43(24):e45-58.Full text Abstract
241. Smit EF, Felip E, Uprety D, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024 Apr;25(4):439-54. Abstract
242. Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021 Nov 9;375:n2363. Abstract
243. Ferrara R, Imbimbo M, Malouf R, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257.Full text Abstract
244. Kanabar SS, Tiwari A, Soran V, et al. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax. 2022 Dec;77(12):1163-74. Abstract
245. Socinski MA, Jotte RM, Cappuzzo F, et al. Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol. 2023 Apr 1;9(4):527-35.Full text Abstract
246. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec 20;39(36):4073-126. [Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315.]Full text Abstract
247. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.Full text Abstract
248. Beavers CJ, Rodgers JE, Bagnola AJ, et al. Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation. 2022 Apr 12;145(15):e811-e38.Full text Abstract
249. Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J. 2022 Nov 7;43(42):4458-68.Full text Abstract
250. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-33.Full text Abstract
251. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-30. Abstract
252. Jassem J, de Marinis F, Giaccone G, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J Thorac Oncol. 2021 Nov;16(11):1872-82. Abstract
253. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020 Oct 1;383(14):1328-39.Full text Abstract
254. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021 Feb 13;397(10274):592-604. Abstract
255. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-01.Full text Abstract
256. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019 May;7(5):387-401. Abstract
257. Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022 Nov;28(11):2374-80.Full text Abstract
258. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. Abstract
259. Johnson ML, Cho BC, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol. 2023 Feb 20;41(6):1213-27.Full text Abstract
260. Gijtenbeek RG, de Jong K, Venmans BJ, et al. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Database Syst Rev. 2023 Jul 7;7(7):CD013382.Full text Abstract
261. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018 Oct 1;36(28):2872-8. Abstract
262. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.Full text Abstract
263. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51.Full text Abstract
264. Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014 Oct;15(11):1254-62. Abstract
265. Pilkington G, Boland A, Brown T, et al. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 2015 Apr;70(4):359-67. Abstract
266. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct 24;374(9699):1432-40. Abstract
267. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Abstract
268. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.Full text Abstract
269. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123-35.Full text Abstract
270. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-33. Abstract
271. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. Abstract
272. Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021 Mar 1;39(7):723-33.Full text Abstract
273. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50. Abstract
274. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-65. Abstract
275. Reck M, Kaiser R, Mellemgaard A, et al; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143-55. Abstract
276. Cortot AB, Audigier-Valette C, Molinier O, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. Eur J Cancer. 2020 May;131:27-36. Abstract
277. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665-73. Abstract
278. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94.Full text Abstract
279. Nakitende D, Gottlieb M, Ruskis J, et al. Ultrasound for confirmation of thoracostomy tube placement by emergency medicine residents. Trauma (United Kingdom). 2015;19(1):35‐8.
280. Jenkins JA, Gharahbaghian L, Doniger SJ, et al. Sonographic identification of tube thoracostomy study (SITTS): confirmation of intrathoracic placement. West J Emerg Med. 2012 Sep;13(4):305-11.Full text Abstract
281. Ford DW, Koch KA, Ray DE, et al. Palliative and end-of-life care in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 suppl):e498S-e512S.Full text Abstract
282. Ahn MJ, Lisberg A, Goto Y, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol. 2025 Jun 12:S1556-0864(25)00761-0.Full text Abstract
283. He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021 Sep;9(9):1021-29. Abstract
284. Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-19. Abstract
285. Zhou C, Wang Z, Sun M, et al. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. Nat Cancer. 2023 Jun;4(6):860-71. Abstract
286. Lu S, Dong X, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022 Sep 20;40(27):3162-71.Full text Abstract
287. Lu S, Dong X, Jian H, et al. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS). Cancer Commun (Lond). 2024 Sep;44(9):1005-17.Full text Abstract
288. ClinicalTrials.gov. Study of eftilagimod alfa (Efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy in participants with metastatic non-small cell lung cancer (NSCLC) (TACTI-004). Oct 2025 [internet publication].Full text
289. ClinicalTrials.gov. APL-101 study of subjects with NSCLC with c-met EXON 14 skip mutations and c-met dysregulation advanced solid tumors (SPARTA). 2024 [internet publication].Full text
290. Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022 Nov;10(11):1019-28.Full text Abstract
291. Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Sep;23(9):1167-79.Full text Abstract
292. Lu S, Zhang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 2024 Jan 16;331(3):201-11.Full text Abstract
293. Wang Z, Wu L, Li B, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023 Jan 20;41(3):651-63.Full text Abstract
294. Shi Y, Chen J, Yang R, et al. Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, phase 3 study (INSPIRE). J Thorac Oncol. 2024 Jan 25;S1556-0864(24)00033-9.Full text Abstract
295. Zhong H, Sun S, Chen J, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024 May;12(5):355-65. Abstract
296. Powell H, Tata L, Baldwin DR, et al. Treatment decisions and survival for people with small cell lung cancer. Brit J Cancer. 2014 Feb 18;110(4):908-15. Abstract
297. Khakwani A, Rich AL, Powell HA, et al. Lung cancer survival In England: trends in non-small cell lung cancer survival over the duration of the National Lung Cancer Audit. Brit J Cancer. 2013 Oct 15;109(8):2058-65. Abstract
298. Oda M, Watanabe Y, Shimizu J, et al. Extent of mediastinal node metastasis in clinical stage I non-small-cell lung cancer: the role of systematic nodal dissection. Lung Cancer. 1998 Oct;22(1):23-30. Abstract
299. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016 Jan;11(1):39-51.Full text Abstract
300. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 1;22(21):4341-50. Abstract
301. Miller KL, Shafman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):64-9. Abstract
302. Colt HG, Murgu SD, Korst RJ, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e437S-e454S.Full text Abstract
303. Schneider BJ, Ismaila N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol. 2020 Mar 1;38(7):753-66.Full text Abstract
304. Grassi L, Caruso R, Riba MB, et al. Anxiety and depression in adult cancer patients: ESMO clinical practice guideline. ESMO Open. 2023 Apr;8(2):101155.Full text Abstract
305. Carlson LE, Ismaila N, Addington EL, et al. Integrative oncology care of symptoms of anxiety and depression in adults with cancer: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 2023 Oct 1;41(28):4562-91.Full text Abstract
306. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010 Jan 21;340:b5569. Abstract
Use of this content is subject to our disclaimer